Patrick Gleason, PharmD, Director of Health Outcomes, Prime Therapeutics, says by 2017, 50% of all expenditures for drugs will be in the specialty drug space.
Patrick Gleason, PharmD, Director of Health Outcomes, Prime Therapeutics, says by 2017, 50% of all expenditures for drugs will be in the specialty drug space. “It suffices to say that it’s pharmaceutical manufacturer price increases that are driving or fueling the specialty drug trend with an increase in utilization, and we foresee this growing in the future,” Dr Gleason said. “What’s really interesting is to look at the expenditures of specialty drugs not just on the pharmacy benefit, but the medical benefit.”
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Use of Voluntary Alignment in the Next Generation ACO Model
June 5th 2025Use of voluntary alignment attribution by Next Generation Accountable Care Organization (ACO) participants was limited. The authors highlight the reasons and describe organizational use cases via a mixed-methods approach.
Read More